ProKidney Corp.
Hayley Squires serves as a Senior Compliance Specialist and Manufacturing Batch Record Reviewer at ProKidney Corp. since November 2023. Prior to this role, Hayley accumulated extensive experience at Talaris Therapeutics, beginning in August 2019, where responsibilities included Supervisor of Manufacturing Operations, Shift Lead, and Manufacturing Operations Technologist II. Earlier experience includes a position as a Laboratory Technician at Eurofins Genomics Americas from August 2015 to August 2019. Hayley holds a Bachelor of Science degree in Biology with a concentration in Cell Physiology from the University of Louisville.
ProKidney Corp.
ProKidney (Nasdaq: PROK), a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases potentially drive meaningful improvement in kidney function. Late-stage CKD, Stage 3b - 4, is a key target for REACT™ therapy. REACT™ has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program, which launched in January 2022. For more information, visit www.prokidney.com.